Tag: heart failure

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...

Simplex Quantum Welcomes Dr. Marco Perez as an Advisor to Advance AI-Driven Heart Failure Detection

TOKYO, July 7, 2025 /PRNewswire/ -- Simplex Quantum, an AI-driven healthcare technology company, is proud to announce that Dr. Marco Perez, Associate Professor of...

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT

Nuevocor Strengthens Board with Appointment of Thierry Abribat

SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr....

Public Advisory – NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug

OTTAWA, ON, July 5, 2025 /CNW/ - Summary Product: NRA-Amlodipine 5 mg, DIN 02476460Issue: Health products - Product safetyWhat to do: Check your bottle of NRA-Amlodipine 5 mg...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Clover Health Set to Join Russell 3000® Index

WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- InterShunt Technologies, Inc., a medical device company focused on...

Tencent Cloud Unveils New AI Agents, WorkBuddy and Miora, Driving Innovation and Real Business Outcomes Across Southeast Asia

CDP Announces Transformative Investment to Accelerate Environmental Transparency Worldwide

Vietnam-aligned OceanLotus pivots to spy on domestic targets as it takes a more selective approach abroad, ESET Research finds

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

Simplex Quantum Welcomes Dr. Marco Perez as an Advisor to Advance AI-Driven Heart Failure Detection

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Nuevocor Strengthens Board with Appointment of Thierry Abribat

Public Advisory – NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Clover Health Set to Join Russell 3000® Index

InterShunt Enrolls First Patient in New Heart Failure Study

Explore

Press Releases

News & Opinion

Living

Others

Follow us